RxDoctor Payments DataLook up a doctor →

Sunder Rao, MD

Cardiovascular Disease · Butler, PANPI 1164497293

Payments from drug & device makers

$326,986in general payments, 2019–2025

Across 1,311 payments — averaging $249.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$159K
  • Boehringer Ingelheim$61K
  • Biotronik Inc.$26K
  • Lilly USA, LLC$17K
  • Amgen$15K
  • Boehringer Ingelheim International GmbH$12K
  • plus $38K from 42 others

What the payments were for

  • Consulting fees$2,5752%
  • Speaking & faculty fees$77,40770%
  • Travel & lodging$1,8202%
  • Food & beverage$27,99125%
  • Education$1160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$326,986 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$106,634
Medicare patients
1,021
Services billed
1,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin665$567,990
EliquisApixaban470$441,271
XareltoRivaroxaban440$439,561
OzempicSemaglutide150$163,170
Repatha SureclickEvolocumab217$150,077
EntrestoSacubitril/Valsartan117$109,710
FarxigaDapagliflozin Propanediol112$105,645
Synjardy XrEmpagliflozin/Metformin Hcl87$72,594
MultaqDronedarone Hcl49$56,208
BrilintaTicagrelor55$50,757
TrulicityDulaglutide42$38,532
WegovySemaglutide29$36,844
VerquvoVericiguat35$35,800
Praluent PenAlirocumab48$28,027
VascepaIcosapent Ethyl26$12,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Pradaxa$61,375$645,238763 claims
PfizerEliquis$815$441,271470 claims
Johnson & JohnsonXarelto$3,347$439,561440 claims
Novo NordiskOzempic, Wegovy$1,377$200,014179 claims
AstraZenecaFarxiga, Brilinta$7,536$156,402167 claims
NovartisEntresto$158,803$109,710117 claims
Sanofi-aventis U.S. LLCMultaq$5,104$56,20849 claims
Lilly USA, LLCTrulicity$16,639$38,53242 claims
MerckVerquvo$382$35,80035 claims
Lexicon Pharmaceuticals, Inc.Inpefa$217$10,62511 claims
Esperion Therapeutics, Inc.Nexletol$270$4,51711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Butler

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →